ZYME

#1712
Zymeworks Inc. - Common Stock
25.1 3 USD
-1.37%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
25.13
25.13
1年のレンジ
16.00
29.75
1日の変化
-1.37%
月次変化
-10.17%
6か月変化
-5.03%
1年の変化
+41.66%
以前の終値
25.4 8
Open
25.1 3
安値
25.1 3
High
25.1 3
ボリューム
112
チャート全体を表示 Full chart

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 1.84 B
  • Employee 264
  • Founded 2003
  • CEO Kenneth Galbraith
  • Website www.zymeworks.com
  • Headquarter Delaware, United States
  • FIGI BBG019XSYC89
  • Industry 生物工学
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-24.38
売上高対価格比率
18.74

Zymeworks Inc. - Common Stock

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.

ニュース